Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $3.32 USD
Change Today -0.04 / -1.19%
Volume 6.8K
MBLX On Other Exchanges
MBLX is not on other exchanges.
As of 8:10 PM 07/28/15 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

21 Erie Street

Cambridge, MA 02139

United States

Phone: 617-583-1700

Fax: 617-583-1768

Metabolix, Inc., a bioscience company, focuses on delivering sustainable solutions to the plastics and chemicals industries. The company’s targeted markets of plastics and chemicals offer substantial opportunity for innovation and value creation. It focuses on a family of biopolymers found in nature called polyhydroxyalkanoates (PHAs), which occur naturally in living organisms and are chemically similar to polyesters. The company has core capabilities in microbial genetics, fermentation process engineering, chemical engineering, polymer science, plant genetics and botanical science. PHA Biopolymers Platform The company holds exclusive rights to the Metabolix technology and intellectual property used in the joint venture. It acquired all of Telles's product inventory and compounding raw materials, all product certifications and all product trademarks, including Mirel and Mvera, and it retained all co-funded pilot plant equipment in locations outside of the Archer Daniels Midland Company commercial manufacturing facility in Clinton, Iowa. Biobased Industrial Chemicals Platform The company is developing C4 and C3 chemicals from biobased sources, as opposed to the fossil fuels that are used to produce most industrial chemicals. The company’s process for creating biobased industrial C4 and C3 chemicals involves engineering metabolic pathways into microbes that, in a fermentation process, produce specific PHA structures that serve as precursors for these chemicals. Crops Platform The company is harnessing the renewable nature of plants to make renewable chemicals and bioenergy from crops. The company is working to create proprietary systems to produce PHB in high concentration in the leaves of biomass crops or in the seeds of oilseed crops for these multiple applications. Strategy Key elements of the company’s strategy include creating a product portfolio of proprietary biopolymers and biopolymer formulations; establishing a supply chain for PHA biopolymers; sourcing complementary biopolymers; managing existing inventory; market positioning and technical support; continuing microbial research and process development; extending its technology to sustainable production of biobased chemicals and intermediates; advancing plant crop research; partnering its programs; and furthering its leading and competitive intellectual property position. Intellectual Property The company owns approximately 380 issued patents and approximately 140 patent applications worldwide, and it has licensed from third parties approximately 25 issued patents and patent applications worldwide. In 2013, the company filed approximately 50 patent applications worldwide, including applications for 5 new inventions covering biodegradable films, PHAs as additives for polymer applications, and the use of PHA-containing biomass to produce biobased industrial chemicals, as well as alternate feedstocks for producing novel biobased chemicals from genetically engineered microbes. The company were also granted or allowed 15 patent applications in 2013, 7 in the United States of America and 8 internationally. The company’s extensive patent portfolio covers, among other things, the fundamental biotechnology needed to produce Mirel biopolymers and a range of biobased chemicals, as well as biopolymer compositions, processes and derived products. The licensed patents and patent applications include patents covering its core technology that are owned by Massachusetts Institute of Technology and exclusively licensed to the company. The company’s intellectual property portfolio includes patents directed to compositions of polymers, genes, vectors, expression systems in plants and microbes, polymer compositions of matter and formulations, devices, coatings and films, as well as methods of manufacture and use. The terms of such patents are set to expire at various times between 2014 and 2032. The company’s registered U.S. trademarks include Metabolix, the Metabolix four-leaf design, Telles, Mirel, the Mirel heart-leaf design, Mvera and Biopol. These marks and certain other trademarks have also been registered in selected foreign countries. Research and Development Expenses During the year ended December 31, 2013, the company spent approximately $19.1 million on company-sponsored research and development activities. Competition The company competes with Genomatica, Myriant, BioAmber, OPX/Dow, Cargill/Novozymes, and Novomer. History The company was founded in 1992. It was incorporated in Massachusetts in 1992 under the name Metabolix, Inc. In 1998, the company reincorporated in Delaware.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MBLX:US $3.32 USD -0.04

MBLX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Biome Technologies PLC 139.00 GBp 0.00
Corbion NV €18.97 EUR +0.20
Kaneka Corp ¥866.00 JPY +9.00
Showa Denko KK ¥152.00 JPY 0.00
Teijin Ltd ¥467.00 JPY +14.00
View Industry Companies

Industry Analysis


Industry Average

Valuation MBLX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 26.8x
Price/Book 5.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales 22.1x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact METABOLIX INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at